Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Conference to Clinic: Recent Advances in Biomarker-Driven Treatment of GI Cancers
  • CME
  • MOC

Credits Available
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
ABIM MOC: maximum of 1.0 Medical Knowledge MOC point(s)
Released: August 10, 2021 Expiration: August 9, 2022
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bayer HealthCare Pharmaceuticals Inc.
Merck Sharp & Dohme Corp.
Allison M. Cushman-Vokoun, MD, PhD
John L. Marshall, MD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Discuss the expanding role and increasing importance of biomarker testing that can guide the selection of therapy for patients with GI malignancies in the era of precision oncology
  • Describe current and emerging testing methods/tools for identifying actionable biomarkers in patients with GI malignancies
  • Analyze data from clinical trials of precision therapies in select GI malignancies and use this information to guide evidence-based care
  • Become familiar with the design of ongoing clinical trials for novel biomarker-driven treatment strategies in GI malignancies, and counsel appropriate patients about availability and participation

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Allison M. Cushman-Vokoun, MD, PhD

Associate Professor
Department of Pathology and Microbiology
University of Nebraska Medical Center
Medical Director
Molecular Diagnostics Laboratory and Human Genetics Laboratory
Department of Pathology and Microbiology
Nebraska Medicine
Omaha, Nebraska

Allison M. Cushman-Vokoun, MD, PhD, FCAP, has disclosed that she has received other financial or material support from ThermoFisher Scientific.
John L. Marshall, MD

Chief, Division of Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

John L. Marshall, MD, has disclosed that he has received consulting fees from Bayer, Caris, Indivumed, Daiichi Sankyo, and Taiho; salary from Indivumed; and fees for non-CME services from Bayer, Daiichi Sankyo, Merck, Pfizer, and Taiho.

Staff

Ryan P. Topping, PhD

Scientific Director

Ryan P. Topping, PhD, has no relevant conflicts of interest to report.
Shara Pantry, PhD
Shara Pantry, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.
Krista Marcello

Associate Director, Educational Strategy

Krista Marcello has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This educational program is intended for oncologists, pathologists, and other healthcare professionals involved in precision testing and treatment of GI malignancies.

Goal

The goal of this activity is to improve the knowledge, confidence, competence, and performance of learners to optimally integrate current and emerging biomarkers to guide treatment decisions for patients with select GI malignancies.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 10, 2021, through August 09, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Introduction
  • CME
  • MOC

Loading...
An introduction to the experts and the program, with interactive polling questions.
Allison M. Cushman-Vokoun, MD, PhD
John L. Marshall, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
ABIM MOC: maximum of 1.0 Medical Knowledge MOC point(s)
Released: August 10, 2021 Expiration: August 9, 2022

This program is divided into short chapters that you can step through using the Video Chapters menu.
PreviousNext

Related Content

In this slideset from Clinical Care Options (CCO), experts discuss their thoughts on dosing of regorafenib and TAS-102 for colorectal cancer (CRC).

Kanwal Raghav, MD person default Rachel Riechelmann, MD, PhD Released: October 21, 2021

Short slideset on key trials and approvals for first-generation TRK inhibitors in NTRK fusion+ solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: October 15, 2021

Short expert slideset on when and how to test for NTRK fusions in various solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: October 8, 2021

Expert commentary on the use of PARP inhibitors in the treatment of pancreatic cancer, from Clinical Care Options (CCO)

Dirk Arnold, MD, PhD Released: October 5, 2021

Video Chapters


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bayer HealthCare Pharmaceuticals Inc.
Merck Sharp & Dohme Corp.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue